Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab may be more effective at extending survival in patients with NLPHL than the usual approach with rituximab.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony przez lekarza specjalistę chłoniak Hodgkina typu NLPHL.
- •Chłoniak nieleczony (stadium IB-IV) lub leczony wcześniej.
- •Pacjent potrzebuje leczenia ze względu na objawy (gorączka, utrata wagi, nocne poty), objawową chorobę lub na własne życzenie.
- •Choroba jest widoczna w badaniach obrazowych.
- •Wiek co najmniej 18 lat.
- •Pacjent jest w stanie samodzielnie funkcjonować lub z niewielką pomocą.
- •Wyniki badań krwi wskazują na odpowiednią liczbę białych krwinek i płytek krwi.
- •Wydolne nerki i wątroba.
✗ Disqualifies
- •Pacjenci poniżej 18 roku życia.
- •Pacjenci z nieprawidłowymi wynikami niektórych badań krwi (np. zbyt niski poziom neutrofilów lub płytek krwi).
- •Pacjenci z chorobami wątroby lub nerek, które nie mieszczą się w określonych normach.
- •Pacjenci, u których badanie potwierdziło obecność wirusa HIV, ale nie byli leczeni lub mają wykrywalną wiremię.
- •Pacjenci z aktywnym zapaleniem wątroby typu B, które nie jest kontrolowane przez leczenie.
- •Pacjenci, którzy nie spełniają kryteriów dotyczących stanu ogólnego lub chorób towarzyszących.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (36)
City of Hope Comprehensive Cancer Center
Duarte, United States
UM Sylvester Comprehensive Cancer Center at Aventura
Aventura, United States
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, United States
UM Sylvester Comprehensive Cancer Center at Coral Springs
Coral Springs, United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, United States
UM Sylvester Comprehensive Cancer Center at Doral
Doral, United States
UM Sylvester Comprehensive Cancer Center at Hollywood
Hollywood, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, United States
UM Sylvester Comprehensive Cancer Center at Kendall
Miami, United States
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, United States
Emory University Hospital/Winship Cancer Institute
Atlanta, United States
University of Kansas Cancer Center
Kansas City, United States
University of Kansas Cancer Center-Overland Park
Overland Park, United States
University of Kansas Hospital-Westwood Cancer Center
Westwood, United States
University of Kansas Cancer Center - Briarcliff
Kansas City, United States
University of Kansas Cancer Center - North
Kansas City, United States
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, United States
University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, United States
Memorial Sloan Kettering Basking Ridge
Basking Ridge, United States
Memorial Sloan Kettering Monmouth
Middletown, United States
Memorial Sloan Kettering Bergen
Montvale, United States
Memorial Sloan Kettering Commack
Commack, United States
Memorial Sloan Kettering Westchester
Harrison, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Memorial Sloan Kettering Nassau
Uniondale, United States
Wake Forest University Health Sciences
Winston-Salem, United States
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Cincinnati Cancer Center-West Chester
West Chester, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, United States
UT MD Anderson Cancer Center
Houston, United States
Huntsman Cancer Institute/University of Utah
Salt Lake City, United States
University of Virginia Cancer Center
Charlottesville, United States
VCU Massey Comprehensive Cancer Center
Richmond, United States
University Health Network-Princess Margaret Hospital
Toronto, Canada
Trial contact
Site Public Contact
Alex F. Herrera
PRINCIPAL_INVESTIGATOR
Site Public Contact
Michele Stanchina
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Pamela B. Allen
PRINCIPAL_INVESTIGATOR
Site Public Contact
Marc S. Hoffmann
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Raphael E. Steiner
PRINCIPAL_INVESTIGATOR
Site Public Contact
Rakhee Vaidya
PRINCIPAL_INVESTIGATOR
Site Public Contact
Zulfa Omer
PRINCIPAL_INVESTIGATOR
Site Public Contact
Yun Choi
PRINCIPAL_INVESTIGATOR
Site Public Contact
Sami Ibrahimi
PRINCIPAL_INVESTIGATOR
Site Public Contact
Dai Chihara
PRINCIPAL_INVESTIGATOR
Site Public Contact
Allison Bock
PRINCIPAL_INVESTIGATOR
Site Public Contact
Nathan L. Roberts
PRINCIPAL_INVESTIGATOR
Site Public Contact
Bruce O. Hough
PRINCIPAL_INVESTIGATOR
Site Public Contact
Anca Prica
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.